Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Mercaptopurine
Drug ID BADD_D01392
Description An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
Indications and Usage For remission induction and maintenance therapy of acute lymphatic leukemia.
Marketing Status Prescription
ATC Code L01BB02
DrugBank ID DB01033
KEGG ID D00161
MeSH ID D015122
PubChem ID 667490
TTD Drug ID D09UZO
NDC Product Code 60763-601; 69076-913; 15308-0712; 12780-0299; 62991-2899; 0378-3547; 0054-4581; 38779-1427
Synonyms Mercaptopurine | 6H-Purine-6-thione, 1,7-dihydro- | 6-Mercaptopurine Monohydrate | 6 Mercaptopurine Monohydrate | 6-Thiopurine | 6 Thiopurine | 1,7-Dihydro-6H-purine-6-thione | 6-Mercaptopurine | 6 Mercaptopurine | 6-Thiohypoxanthine | 6 Thiohypoxanthine | Purinethol | Puri-Nethol | Mercaptopurina Wellcome | Leupurin | BW 57-323H | BW 57 323H | BW 57323H | Purimethol | Mecaptopurine Anhydrous
Chemical Information
Molecular Formula C5H4N4S
CAS Registry Number 50-44-2
SMILES C1=NC2=C(N1)C(=S)N=CN2
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Adverse drug reactionNuclear receptor subfamily 4 group A member 3Q92570T9394912709428; 12082103; 15956351; 16604165
ApoptosisNuclear receptor subfamily 4 group A member 3Q92570T9394912709428; 12082103; 15956351; 16604165
ArteriosclerosisNuclear receptor subfamily 4 group A member 3Q92570T9394912709428; 12082103; 15956351; 16604165
Bone marrow toxicityThiopurine S-methyltransferaseP51580Not Available15228171; 9893619; 12525681
InflammationNuclear receptor subfamily 4 group A member 3Q92570T9394912709428; 12082103; 15956351; 16604165
Nervous system disordersNuclear receptor subfamily 4 group A member 3Q92570T9394912709428; 12082103; 15956351; 16604165
Soft tissue neoplasms malignant and unspecifiedNuclear receptor subfamily 4 group A member 3Q92570T9394912709428; 12082103; 15956351; 16604165
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cough22.02.03.001--
Crohn's disease10.02.01.005; 07.08.01.0150.038491%Not Available
Cyst16.02.02.002; 08.03.05.001--Not Available
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Diarrhoea haemorrhagic24.07.02.004; 07.02.01.0020.007698%Not Available
Diffuse large B-cell lymphoma16.28.02.001; 01.15.02.0010.007531%Not Available
Dyspnoea22.02.01.004; 02.01.03.002--
Encephalopathy17.13.02.0010.003849%
Enteritis07.08.03.0020.005774%
Epstein-Barr virus infection11.05.10.0040.003849%
Erythema nodosum10.02.01.020; 23.07.02.0010.003849%Not Available
Fatigue08.01.01.002--
Febrile neutropenia08.05.02.004; 01.02.03.0020.002008%
Gastrointestinal disorder07.11.01.001--Not Available
Haematochezia07.12.02.003; 24.07.02.0120.003849%Not Available
Headache17.14.01.001--
Hepatic encephalopathy17.13.01.003; 09.01.03.0060.005774%Not Available
Hepatic fibrosis24.08.06.002; 09.01.04.0020.003849%Not Available
Hepatic necrosis09.01.07.002--
Hepatocellular injury09.01.07.0080.005774%Not Available
Hepatotoxicity12.03.01.008; 09.01.07.0090.011547%Not Available
Herpes zoster23.09.03.002; 11.05.02.0030.011547%
Hyperhidrosis23.02.03.004; 08.01.03.0280.005774%
Hypersensitivity10.01.03.003--
Hyperuricaemia14.09.01.003--
Hypoaesthesia17.02.06.0230.013472%Not Available
Hypoglycaemia14.06.03.001; 05.06.03.0010.036567%
Immune system disorder10.02.01.001--Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 6 Pages